350 related articles for article (PubMed ID: 29675401)
1. Analysis of the Antigenic and Prophylactic Properties of the
Garde E; Ramírez L; Corvo L; Solana JC; Martín ME; González VM; Gómez-Nieto C; Barral A; Barral-Netto M; Requena JM; Iborra S; Soto M
Front Cell Infect Microbiol; 2018; 8():112. PubMed ID: 29675401
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.
Soto M; Corvo L; Garde E; Ramírez L; Iniesta V; Bonay P; Gómez-Nieto C; González VM; Martín ME; Alonso C; Coelho EA; Barral A; Barral-Netto M; Iborra S
PLoS Negl Trop Dis; 2015 May; 9(5):e0003751. PubMed ID: 25955652
[TBL] [Abstract][Full Text] [Related]
3. A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis.
Martins VT; Duarte MC; Chávez-Fumagalli MA; Menezes-Souza D; Coelho CS; de Magalhães-Soares DF; Fernandes AP; Soto M; Tavares CA; Coelho EA
Parasit Vectors; 2015 Jul; 8():363. PubMed ID: 26160291
[TBL] [Abstract][Full Text] [Related]
4. Leishmania infantum transfected with toxic plasmid induces protection in mice infected with wild type L. infantum or L. amazonensis.
Zorgi NE; Arruda LV; Paladine I; Roque GAS; Araújo TF; Brocchi M; Barral M; Sanchiz Á; Requena JM; Abánades DR; Giorgio S
Mol Immunol; 2020 Nov; 127():95-106. PubMed ID: 32949849
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with Leishmania infantum acidic ribosomal P0 but not with nucleosomal histones proteins controls Leishmania infantum infection in hamsters.
Pereira L; Abbehusen M; Teixeira C; Cunha J; Nascimento IP; Fukutani K; dos-Santos W; Barral A; de Oliveira CI; Barral-Netto M; Soto M; Brodskyn CI
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003490. PubMed ID: 25642946
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.
de Jesus Pereira NC; Régis WC; Costa LE; de Oliveira JS; da Silva AG; Martins VT; Duarte MC; de Souza JR; Lage PS; Schneider MS; Melo MN; Soto M; Soares SA; Tavares CA; Chávez-Fumagalli MA; Coelho EA
Exp Parasitol; 2015 Jun; 153():180-90. PubMed ID: 25845753
[TBL] [Abstract][Full Text] [Related]
7. A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum.
Pirdel L; Farajnia S
Scand J Immunol; 2017 Jul; 86(1):15-22. PubMed ID: 28426153
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic properties of a Leishmania-specific hypothetical protein in a murine model of visceral leishmaniasis.
Lage DP; Martins VT; Duarte MC; Garde E; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
Parasite Immunol; 2015 Dec; 37(12):646-56. PubMed ID: 26457798
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.
Chávez-Fumagalli MA; Costa MA; Oliveira DM; Ramírez L; Costa LE; Duarte MC; Martins VT; Oliveira JS; Olortegi CC; Bonay P; Alonso C; Tavares CA; Soto M; Coelho EA
Microbes Infect; 2010 Nov; 12(12-13):967-77. PubMed ID: 20601076
[TBL] [Abstract][Full Text] [Related]
10. A recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection.
Martins VT; Lage DP; Duarte MC; Carvalho AM; Costa LE; Mendes TA; Vale DL; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
Cell Immunol; 2017 Mar; 313():32-42. PubMed ID: 28049560
[TBL] [Abstract][Full Text] [Related]
11. SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection.
Silvestre R; Cordeiro-Da-Silva A; Santarém N; Vergnes B; Sereno D; Ouaissi A
J Immunol; 2007 Sep; 179(5):3161-70. PubMed ID: 17709531
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
13. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
Front Immunol; 2018; 9():465. PubMed ID: 29599776
[TBL] [Abstract][Full Text] [Related]
14. Probing the efficacy of a heterologous Leishmania/L. Viannia braziliensis recombinant enolase as a candidate vaccine to restrict the development of L. infantum in BALB/c mice.
Santos TTO; Martins VT; Lage DP; Costa LE; Salles BCS; Carvalho AMRS; Dias DS; Ribeiro PAF; Chávez-Fumagalli MA; Machado-de-Ávila RA; Roatt BM; de Magalhães-Soares DF; Menezes-Souza D; Coelho EAF; Duarte MC
Acta Trop; 2017 Jul; 171():8-16. PubMed ID: 28288798
[TBL] [Abstract][Full Text] [Related]
15. Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species.
Lage DP; Martins VT; Duarte MC; Costa LE; Tavares GSV; Ramos FF; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CAP; Coelho EAF
Acta Trop; 2016 Jun; 158():220-230. PubMed ID: 26976272
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
[TBL] [Abstract][Full Text] [Related]
17. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge.
Marques-da-Silva EA; Coelho EA; Gomes DC; Vilela MC; Masioli CZ; Tavares CA; Fernandes AP; Afonso LC; Rezende SA
Parasitol Res; 2005 Dec; 98(1):67-74. PubMed ID: 16261353
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
19. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
[TBL] [Abstract][Full Text] [Related]
20. The Leishmania infantum acidic ribosomal protein LiP2a induces a prominent humoral response in vivo and stimulates cell proliferation in vitro and interferon-gamma (IFN-gamma) production by murine splenocytes.
Soto M; Alonso C; Requena JM
Clin Exp Immunol; 2000 Nov; 122(2):212-8. PubMed ID: 11091277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
